290 likes | 812 Views
Amphotericin B. Two-edged sword or Swiss army knife? Bridging the gap between Alzheimer’s and Prion diseases. What are some Amyloid Diseases?. Alzheimer’s disease Atrial Amyloidosis Hereditary Renal Amyloidosis Secondary Systematic Amyloidosis Injection-Localized Amyloidosis .
E N D
Amphotericin B Two-edged sword or Swiss army knife? Bridging the gap between Alzheimer’s and Prion diseases.
What are some Amyloid Diseases? • Alzheimer’s disease • Atrial Amyloidosis • Hereditary Renal Amyloidosis • Secondary Systematic Amyloidosis • Injection-Localized Amyloidosis
What are some Prion Diseases? • Chronic Wasting Disease (CWD) • Scrapie • BSE- Mad Cow Disease • Kuru • Creutzfeldt-Jakob Disease
Amyloids vs Prions • Prions are known to be infectious in their spreading to different hosts, e.g. CWD, BSE, kuru, etc… • Amyloid diseases - not thought to be infectious agents but….
Amyloids vs. Prions-news! • It has been recently shown that mice who were fed amyloid fibrils (from the spleen of infected mice) orally (in H2O) developed amyloid deposits upon stimulation.
Amyloids vs. Prions, pt. II • Similar propagation of fibrils in vitro. • Similar symptoms (inflammatory neuropathies) and adverse affects from having the disease.
These diseases involve fibril deposits: What is a fibril? • Normal PrP or Ab protein may misfold into a beta sheet structure • The beta sheets form extended aggregate fiber structures by “recruiting” properly folded proteins • These fibrils are protease resistant and insoluble • This is the most prevalent characteristic of amyloid and prion diseases. Prion Protein-PrP
Possible approaches to treating Amyloid and Prion Diseases. • 1. Physical blockage of fibril growth (by small molecules). • 2. Alter processing/clearance of protein (enzyme inhibitors) • 3. Damage Control of existing fibrils(?) (NSAIDs -- Non-steroidal Anti- Inflammatory Drugs, Statins) • 4.Symptomatic (anticholinergics) • 5. Effecting an immune response. • Specific-vaccine • Non-Specific-general stimulant
How would Physical Blockage work? • Congo Red: a molecule that binds to and inhibits fibril growth. • Congo Red is an azo dye that was used by Alois Alzheimer to characterize brains with Alzheimer’s disease • Some other in vitro success using N-methylated peptides, anti-sense peptides and other small molecules.
AD model system #1:Characterizing fibrils • Congo Red binds to fibrils very specifically. • Absorbance at 540 nm can be used to quantitate [fibril] formation • The Insulin Fibril system was used as it is a proven amyloid model system.
Hypothesis: • AmB is one of the only agents known to slow prion diseases in animal models (hamster,mouse)! • Perhaps AmB could act by the 1st mechanism by binding to existing fibrils and preventing growth, thus preventing the propagation of the disease.
Why AmB? • Amphotericin B is an antifungal drug used to treat immuno-compromised people (AIDS, cancer) who have deep fungal infections. • Amphotericin B is also an interesting molecule that has a polyene side and a polyol side, which may hint to its binding characteristics. • It is also a relatively inexpensive drug that is already on the market.
417 nm Does AmB bind to fibrils? • Yes it does! • Although the actual binding site(s) are unknown, it does bind to fibrils specifically and not to protein in native form. • 1 mole AmB/2 mole insulin • Kd~1.1µM
Does AmB B inhibit insulin Fibril Formation? • No it doesn’t. • Luckily it does not induce fibrils either • Thus, AmB neither inhibits nor promotes fibril formation under these conditions (pH 2-HCl).
Ab 25-35 • Minimal “Alzheimer’s unit?” • Rapidly fibrillizes(~1 hr) • Can promote protein denaturation-”anti chaperone” • Is cytotoxic and neurotoxic likeAb • Our titration of the Ab25-35 fibrils with Congo Red shows ~1 “fibril peptide” per Congo Red.
But…does AmB B inhibit Ab 25-35 Fibril Formation? • Yes it does!! At reasonable therapeutic concentrations, too (7.5 and 15µM) • However, it only delays the onset of fibrillogenesis;it does not change final concentration • Ab 1-40 and PrP peptides will be the real test.
How else might Amphotericin B work in addition to fibril inhibition? • Amphotericin B may work non-specifically. Because of its properties and known prior use, it may be able to activate the generalized immune system acute phase response (IL-1, IL-6) and promote removal of amyloid or prion deposits. Fibrils may also help sequester AmB in tissues most strongly affected. • Previous reports have shown that introducing AmB 2 weeks prior or immediately with the systematic prion inoculum effectively slows the course of the prion infection. Later treatment is less effective. • It might bind to and modify oligomer ion channel properties associated with amyloid diseases. • AmB would selectively associate with cholesterol-rich membrane “rafts” and alter processing (Ab) or conversion(PrP). • Vaccination analog, i.e. could AmB-protein adduct resemble a fibril and lead to antibody/T-cell response?(But.. SCID mice.)
Conclusions • Amphotericin B binds specifically to two different b fibril models suggesting a possible mechanism for its demonstrated antiprion activity. • This is further supported by the kinetic inhibition of Ab 25-35 fibrillization by AmB and suggests a possible screening assay for future potential drugs • Further testing on PrP and Ab2 confirm thishypothesis • As a sidelight, it seems worth investigating whether the fungal amyloid-like protein hydrophobin may be important to AmB susceptibility/resistance
THANKS ! Ted Weiland Emily Bauer and Evan Kwong NSF for $$$$$$$ Rachel Nauss
Projects in our lab • Physical characterization of Amphotericin B drug delivery vehicles (stability, ion channel formation) • Pharmaceutical testing of new AmB preparations (with K. Wasan) • Cytokine expression profiles caused by AmB preps in immune cells (with L. Turtinen) • Localization and metabolism of liposomal doxorubicin in single cells (with E. Arriaga) • AmB potential effects on amyloid diseases